Cooper, Jason P., Storer, Barry E., Granot, Noa, Gyurkocza, Boglarka, Sorror, Mohamed L., Chauncey, Thomas R., Shizuru, Judith, Franke, Georg-Nikolaus, Maris, Michael B., Boyer, Michael, Bruno, Benedetto, Sahebi, Firoozeh, Langston, Amelia A., Hari, Parameswaran, Agura, Edward D., Petersen, Soren Lykke, Maziarz, Richard T., Bethge, Wolfgang, Asch, Julie, Gutman, Jonathan A., Olesen, Gitte, Yeager, Andrew M., Hubel, Kai, Hogan, William J., Maloney, David G., Mielcarek, Marco, Martin, Paul J., Flowers, Mary E. D., Georges, George E., Woolfrey, Ann E., Deeg, H. Joachim, Scott, Bart L., McDonald, George B., Storb, Rainer and Sandmaier, Brenda M. (2021). Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies improved outcomes over two decades. Haematologica, 106 (6). S. 1599 - 1608. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Full text not available from this repository.

Abstract

We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past 20 years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypothesized that improvements in clinical practice led to better transplantation outcomes over time. From 1997-2017, 1,720 patients with hematologic malignancies received low-dose total body irradiation +/- fludarabine or clofarabine before transplantation from HLAmatched sibling or unrelated donors, followed by mycophenolate mofetil and a calcineurin inhibitor +/- sirolimus. We compared outcomes in three cohorts by year of transplantation: 1997-2003 (n=562), 2004-2009 (n =594), and 2010-2017 (n=564). The proportion of patients >= 60 years old increased from 27% in 1997-2003 to 56% in 2010-2017, and with scores from the Hematopoietic Cell Transplantation Comorbidity Index of >= 3 increased from 25% in 1997-2003 to 45% in 2010-2017. Use of unrelated donors increased from 34% in 1997-2003 to 65% in 2010-2017. When outcomes from 2004-2009 and 2010-2017 were compared to 1997-2003, improvements were noted in overall survival (P=0.0001 for 2004-2009 and P <= 0.0001 for 2010-2017), progression-free survival (P=0.002 for 2004-2009 and P<0.0001 for 2010-2017), non-relapse mortality (P<0.0001 for 20042009 and P<0.0001 for 2010-2017), and in rates of grades 2-4 acute and chronic graft-versus-host disease. For patients with hematologic malignancies who underwent transplantation with non-myeloablative conditioning, outcomes have improved during the past two decades.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Cooper, Jason P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Storer, Barry E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Granot, NoaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gyurkocza, BoglarkaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sorror, Mohamed L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chauncey, Thomas R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Shizuru, JudithUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Franke, Georg-NikolausUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Maris, Michael B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boyer, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bruno, BenedettoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sahebi, FiroozehUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Langston, Amelia A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hari, ParameswaranUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Agura, Edward D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Petersen, Soren LykkeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Maziarz, Richard T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bethge, WolfgangUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Asch, JulieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gutman, Jonathan A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Olesen, GitteUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Yeager, Andrew M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hubel, KaiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hogan, William J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Maloney, David G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mielcarek, MarcoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Martin, Paul J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Flowers, Mary E. D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Georges, George E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Woolfrey, Ann E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Deeg, H. JoachimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scott, Bart L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
McDonald, George B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Storb, RainerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sandmaier, Brenda M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-606604
DOI: 10.3324/haematol.2020.248187
Journal or Publication Title: Haematologica
Volume: 106
Number: 6
Page Range: S. 1599 - 1608
Date: 2021
Publisher: FERRATA STORTI FOUNDATION
Place of Publication: PAVIA
ISSN: 0390-6078
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
VERSUS-HOST-DISEASE; POLYMERASE-CHAIN-REACTION; CYTOMEGALOVIRUS-INFECTION; URSODEOXYCHOLIC ACID; PREEMPTIVE THERAPY; CANCER-PATIENTS; PROPHYLAXIS; MORTALITY; RISK; TRIALMultiple languages
HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60660

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item